ANT-GROUP
Nike today announced that it has joined Ant Group’s Green Energy Initiative and launched an official mini program on Alipay, the leading digital open platform, to encourage more consumers to recycle worn-out shoes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005601/en/
Students play basketball on Nike Grind court (Photo: Business Wire)
Chinese consumers can search the mini program “Recycle-A-Shoe” in the Alipay app and have worn-out Nike shoes collected for recycling. The shoes will then be dismantled and re-processed to make sustainable sport courts through Nike Grind technology. By doing so, consumers will receive virtual green energy points in Alipay Ant Forest, a green mini program. These green energy points can be used to support tree planting, ecological restoration or bio-diversity conservation projects.
“In China, Nike continues to strive toward its goal of ‘Move to Zero’ and encourages the public to take part in environmental protection. The innovative cooperation with Ant Group allows Nike’s Recycle-A-Shoe program to reach more consumers through digital solutions on the Alipay platform and incorporates Nike’s sustainability efforts into daily life, which is our long-term commitment,” said Stanley Chang, Vice President of Operations and Logistics of Nike Greater China.
“In the face of increasing challenges brought on by climate change, the private sector needs to encourage more environmental-friendly actions among consumers while committing themselves to reducing carbon emission in their business operations. We are delighted to partner with Nike to promote low carbon actions and better protect the environment through innovative solutions in recycling,” said Cheng Jiang, General Manager of Social Good Department, Ant Group.
Nike’s global “Recycle-A-Shoe” program has been active for 30 years. More than 30 million pairs of worn-out shoes and over 120 million pounds of footwear factory materials have been recycled and transformed into innovative sports products, such as basketball courts, soccer fields, running tracks, yoga equipment and interior decoration.
Launched in 2016, Alipay Ant Forest is a green initiative that encourages users to adopt low carbon activities in their daily life, which has attracted over 650 million participants since its inception. Users can gain green energy points for low carbon actions, including biking to work instead of driving and paying electricity bills online instead of offline.
Ant Group’s Green Energy Initiative, which features green energy points in Alipay Ant Forest, is open to brands that would like to offer their customers more incentives to take green actions. As of August 2022, the initiative has attracted participation from more than 500 brands across multiple sectors including travel, packaging and home appliance manufacturing.
About Move to Zero
In its commitment to the long-term plan of sustainable development, Nike launched "Move to Zero" in 2019 with the aim of operating with zero carbon emissions and zero waste. This initiative has been implemented across all aspects of design, manufacturing and transportation. Significant progress has also been made in Nike moving closer to its ambitious goal of “Move to Zero”. In September (2022), Nike announced the launch of the CLC Wind Runner Project in the China Logistics Center. After its completion and implementation in early 2023, the Nike China Logistics Center will be operating with 100% renewable energy. In regard to sustainable product innovation, Nike has launched a subversively innovative platform - Nike Forward, which will bring great changes to the apparel industry.
About Alipay
In the evolving digital era, Alipay has transformed from a payment tool of public trust to an open platform for businesses, institutions, service providers, and other partners. Business partners in various industries utilize Alipay to offer consumers a safe and convenient payment experience. Through digital operation, business partners can communicate and provide various commercial and daily life digital services for their clients via Alipay mini programs, lifestyle accounts, and IoT, along with other tools available. Currently, there have been over 80 million businesses serving more than 1 billion consumers via Alipay’s open platform services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005601/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom